Burger A, Dinichert D, Nicod P, Jenny M, Lemarchand-Béraud T, Vallotton M B
J Clin Invest. 1976 Aug;58(2):255-9. doi: 10.1172/JCI108466.
2-n-Butyl-3-(4'-diethylaminoethoxy-3',5'-diiodobenzoyl)-benzofurane (amiodarone), a drug used in arrythmias and angina pectoris, contains 75 mg of organic iodine/200 mg active substance. Four studies were performed to test its effect on thyroid hormone metabolism: (a) nine male subjects were treated with 400 mg of amiodarone for 28 days; (b) five male subjects received, for the same period of time, 150 mg of iodine in the form of Lugol's solution; (c) five subjects received 300 mug L-thyroxine (T4) for 16 days; from the 10th to the 16th day, 400 mg of amiodarone was added; and (d) five euthyroid subjects received 300 mug L-T4 for 16 days. The changes in serum thyroid-stimulating hormone (TSH), serum total T4, 3,5,3'-triiodothyronine (T3), free T3, and 3,5',3'-triiodothyronine (reverse T3, rT3) were measured, and the pituitary reserve in TSH was evaluated by a thyrotropin-releasing hormone (TRH) test. The results show that amiodarone induced a decrease in serum T3 (28+/-5.1 ng/100 ml, mean+/-SEM, P less than 0.0S and 82.7+/-9.3 ng rT3/100 ml, P less than 0.01). The control study with an equal amount of inorganic iodine did not induce these opposite changes but slightly lowered serum rT3, T3, and T4. In the third study, serum rT3 increased as under amiodarone treatment, thereby proving that these changes were peripheral. It is suggested that amiodarone changes thyroid hormone metabolism, possibly by reducing deiodination of T4 to T3 and inducing a preferential production of rT3. Amiodarone also increased the response of TSH to TRH. The maximal increment of serum TSH above base line was 32+/-4.5 muU/ml under treatment and 20+/-3 muU/ml before treatment (P less than 0.01). During this test, the serum T3 increase was more pronounced than during the control period (83+/-13 and 47+/-7.4 ng/100 ml, P less than 0.05).
2 - N - 丁基 - 3 -(4'-二乙氨基乙氧基 - 3',5'-二碘苯甲酰基) - 苯并呋喃(胺碘酮),一种用于治疗心律失常和心绞痛的药物,每200毫克活性物质中含有75毫克有机碘。进行了四项研究以测试其对甲状腺激素代谢的影响:(a)9名男性受试者接受400毫克胺碘酮治疗28天;(b)5名男性受试者在相同时间段内接受150毫克卢戈氏溶液形式的碘;(c)5名受试者接受300微克L - 甲状腺素(T4)治疗16天;从第10天到第16天,添加400毫克胺碘酮;(d)5名甲状腺功能正常的受试者接受300微克L - T4治疗16天。测量血清促甲状腺激素(TSH)、血清总T4、3,5,3'-三碘甲状腺原氨酸(T3)、游离T3和3,5',3'-三碘甲状腺原氨酸(反式T3,rT3)的变化,并通过促甲状腺激素释放激素(TRH)试验评估TSH的垂体储备。结果表明,胺碘酮导致血清T3降低(28±5.1纳克/100毫升,平均值±标准误,P<0.05)和rT3升高(82.7±9.3纳克rT3/100毫升,P<0.01)。等量无机碘的对照研究未引起这些相反的变化,但使血清rT3、T3和T4略有降低。在第三项研究中,血清rT3如在胺碘酮治疗下一样升高,从而证明这些变化是外周性的。提示胺碘酮可能通过减少T4向T3的脱碘作用并诱导rT3的优先产生来改变甲状腺激素代谢。胺碘酮还增加了TSH对TRH的反应。治疗期间血清TSH高于基线的最大增量为32±4.5微单位/毫升,治疗前为20±3微单位/毫升(P<0.01)。在该试验期间,血清T3的增加比对照期更明显(83±13和47±7.4纳克/100毫升,P<0.05)。